2810379750 bmi@hmu.gr


Κατηγορία Ευρωπαϊκό
Τίτλος έργου Computational Horizons in Cancer: Developing Meta- and Hyper-Multiscale Models and Repositories for In Silico Oncology
Φορέας Χρηματοδότησης Ευρωπαϊκή Επιτροπή
Πρόγραμμα FP7, No 600841
Συντονιστής Institute of Communication and Computer Systems – National Technical University of Athens (short name: ICCS) – Greece
  • European Research and Project Office GMBH (short name: EURICE ) – Germany
  • Uninersitaet des Saarlandes (short name: USAAR) – Germany
  • Katholieke Universiteit Leuven (short name: KU Leuven) – Belgium
  • University of Bedfordshire (short name: BED) – United Kingdom
  • The University of Sheffield (short name: USFD) – United Kingdom
  • Foundation for Research and Technology Hellas (short name: FORTH) – Greece
  • Gottfried Wilhelm Leibniz Universitaet Hannover (short name: LUH) – Germany
  • The Trustees of the University of Pennsylvania (short name: USFD) – USA
  • The Chancellor, Masters and Scholars of the University of Oxford (short name: UOFX) – United Kingdom
  • Universita Degli Studi di Torino (short name: UNITO) – Italy
  • Universitaet BERN (short name: UBERN) – Switzerland
  • CUSTODIX NV (short name: CUSTODIX) – Belgium
  • Philips Electronics Nederland B.V (short name: Philips) – The Netherlands
  • University College London (short name: UCL) – United Kingdom
  • SCS SRL (short name: SCS) – Italy
  • Technological Educational Institute of Crete (short name: TEI-C) – Greece
Διάρκεια 01/04/2013 – 31/03/2017
Συνολικός Προϋπολογισμός 13.907.967,00 €
Προϋπολογισμός ΤΕΙ Κρήτης 78.320,00 €
Ιστοσελίδα www.chic-vph.eu
Στόχος έργου

The CHIC proposal aims at developing cutting edge ICT tools, services and secure infrastructure to foster the development of elaborate and reusable integrative models (hypermodels) and larger repositories so as to demonstrate benefits of having both the multiscale data and the correponding models readily available. Although the broader VPH domain is the primary target of the hypermodelling infrastructure to be developed by CHIC, the primary application domain will be cancer and in silico oncology. In the mid and long term CHIC aims to pave the way for reliable in silico clinical trials, lying at the heart of the vision of in silico medicine, and subsequently for patient individualized treatment optimization based on in silico experimentation.